Other Information
−Removed: During the fiscal quarter ended March 31, 2026, no director or officer of the Company adopted or terminated a “Rule 10b5-1 trading arrangement” or a “non-Rule 10b5-1 trading arrangement” (in each case, as defined in Item 408 of Regulation S-K).
+Added: During the fiscal quarter ended June 30, 2026, no director or officer of the Company adopted or terminated a “Rule 10b5-1 trading arrangement” or a “non-Rule 10b5-1 trading arrangement” (in each case, as defined in Item 408 of Regulation S-K).
See Exhibit Index.
22 unchanged sentences
with the SEC on March 29, 2024)
−Removed: Senior Secured Convertible Note, dated as of March 24, 2024, by and among AEON Biopharma, Inc., Daewoong Pharmaceutical Co., LTD.
−Removed: and AEON Biopharma Sub, Inc.
−Removed: (incorporated by reference to Exhibit 4.1 to the Form 8-K filed by the Company with the SEC on March 28, 2024)
−Removed: Senior Secured Convertible Note, dated as of April 12, 2024, by and among AEON Biopharma, Inc., Daewoong Pharmaceutical Co., LTD.
−Removed: and AEON Biopharma Sub, Inc.
−Removed: (incorporated by reference to Exhibit 4.1 to the Form 8-K filed by the Company with the SEC on April 17, 2024)
Description of AEON Biopharma Inc.’s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 (incorporated by reference to Exhibit 4.5 to the Form 10-K filed by the Company with the SEC on August 12, 2024)
1 unchanged sentence
Form of Series B Warrant (incorporated by reference to Exhibit 4.2 to the Form 8-K filed by the Company with the SEC on January 7, 2025)
+Added: Form of Pre-Funded Warrant (incorporated by reference to Exhibit 4.1 to the 8-K filed by the Company with the SEC on July 15, 2026)
+Added: Form of Two-Year Milestone Warrant (incorporated by reference to Exhibit 4.2 to the 8-K filed by the Company with the SEC on July 15, 2026)
+Added: Form of Five-Year Milestone Warrant (incorporated by reference to Exhibit 4.3 to the 8-K filed by the Company with the SEC on July 15, 2026)
+Added: Warrant Agency Agreement, dated as of July 15, 2026, by and between AEON Biopharma, Inc.
+Added: and Continental Stock Transfer & Trust Company, as warrant agent (incorporated by reference to Exhibit 4.4 to the 8-K filed by the Company with the SEC on July 15, 2026)
Certification of Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
15 unchanged sentences
The certification attached as Exhibits 32.1 and 32.2 that accompanies this Quarterly Report on Form 10-Q is not deemed filed with the SEC and is not to be incorporated by reference into any filing of AEON Biopharma, Inc.
−Removed: under the Securities Act of
−Removed: 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Form 10-Q, irrespective of any general incorporation language contained in such filing.
+Added: under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Form 10-Q, irrespective of any general incorporation language contained in such filing.
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
+Added: August 12, 2026
AEON BIOPHARMA, INC.
10 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.